health care Stocks

4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.

Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R&D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.

Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.

Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis.

Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.

Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company's lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.

Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.

Intelicare Holdings Limited (ASX: ICR) is an Australian technology company specializing in AI-powered assistive living solutions for the aged care and disability support sectors. Its flagship InteliCare platform uses sensors and artificial intelligence to monitor the well-being of individuals remotely, providing insights to carers and family members without invasive surveillance. The company primarily operates within the Australian market, aiming to improve independent living outcomes.

Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.

Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.

Vectus Biosystems Limited (ASX: VBS) is an Australian biotechnology company dedicated to the discovery and development of novel small molecule drugs for fibrotic diseases. Their primary focus is on conditions like heart failure and kidney fibrosis, leveraging their expertise in the Renin-Angiotensin-Aldosterone System (RAAS) to progress proprietary drug candidates through pre-clinical and early clinical stages within Australia.

Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.

Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.

Cambium Bio Limited is an Australian clinical-stage biotechnology company focused on developing novel regenerative medicine therapies. Its lead program is centered on a proprietary cell-based treatment for osteoarthritis, aiming to repair damaged cartilage and reduce inflammation. The company's operations are primarily focused on preclinical research and advancing its lead candidate into early-stage human clinical trials.

Control Bionics Limited (ASX: CBL) is a healthcare equipment and services company operating in Australia, focusing on the development and distribution of innovative assistive technologies. Key products include customizable, speech-generating devices for individuals with severe speech and language impairments. Founded in 2016 and listed on the ASX in December 2020.

Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is 'EyeSightAI', targeting the Australian healthcare system and private clinics.

Pacific Edge Limited (ASX: PEB) is a New Zealand-based healthcare company specialising in the development and commercialisation of non-invasive diagnostic tests for the early detection and management of cancer. Its flagship product suite, Cxbladder, focuses on bladder cancer detection and surveillance, primarily targeting the significant US market alongside New Zealand and other international regions.

Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.

Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.

Anatara Lifesciences Ltd (ASX: ANR) is an Australian biotechnology company focused on developing and commercializing novel treatments for gastrointestinal diseases in humans and animals. Operating primarily from Australia, its key product is Anatara's CIC therapy for carbohydrate malabsorption. The company also explores veterinary applications.